Medicus Pharma receives coverage from Stonegate Capital Partners
Published: 10:21 24 Sep 2025 EDT
Medicus Pharma (NASDAQ:MDCX) announced that Stonegate Capital Partners has initiated coverage on the company.
Stonegate analysts wrote that with the closing of its $8 million debenture financing, Medicus has cash of $9.7 million as of the second quarter of 2025, which extends the company’s runway into 2026.
Stonegate also highlighted its acquisition of Antev Limited in Q2, which adds dermatology and infectious disease assets to the company, along with Medicus Pharma’s Memorandum of Understanding (MoU) with Helix Nanotechnologies to develop thermostable infectious disease vaccines.
“Together, these programs position Medicus with a diversified pipeline targeting both near-term specialty indications and longer-term global opportunities," the analysts wrote.
They added that Medicus Pharma management continues to pursue additional high-impact assets to complement this portfolio and leverage its multi-strategy model.
Stonegate Capital analysts said their valuation model returns a valuation range of $14.91 to $29.35 with a midpoint of $21.13 based on a discount rate range of 17.50% to 22.50% and a current risk adjustment range of 50% to 40%. The shares are currently changing hands for $2.64.
